The current consensus is that although preoperative HER2 ECD appears to be correlated with tumor size and nodal involvement, it may not be related to tissue HER2 status, especially in primary breast cancer, and there is insufficient evidence to support incorporating measurement of this parameter into the routine clinical management of women with breast cancer as an independent prognostic factor[14, 34]. The gene discussed is ERBB2; the disease is neoplasm.